Metabolic
SLU-PP-332
A synthetic pan agonist of the estrogen related receptors, a family of nuclear receptors that govern mitochondrial biogenesis and oxidative metabolism. It attracted attention in the popular press as an exercise mimetic.
Where it came from
Developed in Thomas Burris's laboratory at Saint Louis University and later the University of Florida, with the widely reported mouse results published in 2023.
What the literature examines
- ERR alpha, beta and gamma activation
- Mitochondrial biogenesis and oxidative fibre profile in mouse muscle
- Running endurance and metabolic parameters in mice
State of the evidence
There is no human data of any kind. Not a trial, not a case series, nothing.
What a buyer should know
This is the newest and least characterised compound in the catalogue, and the gap between its press coverage and its evidence base is the widest. Pharmacokinetics, chronic safety and off target nuclear receptor effects in humans are simply unknown.
Handling and stability
Small molecule powder. Poor aqueous solubility relative to peptides.
Read it yourself
We do not publish a curated citation list, because a hand picked list of papers is a sales tool. These links run a live query against the public databases, so you see everything, including the results that do not suit us.
Supplied for laboratory research use only. Nothing on this page is a dose, a protocol or a claim of effect in humans, and nothing here is medical advice. Read our research use policy.